Zealand reports Q1 2017 royalty revenue
(WorldNews Denmark)

Company announcement - No. 13/2017 Zealand reports Q1 2017 royalty revenue Zealand reports royalty revenue of DKK 8.0 million in Q1 2017 DKK 5.1 million arises from royalties on sales of Lyxumia®/Adlyxin(TM) DKK 2.9 million arises from royalties on the first sales of Soliqua® 100/33 in the U.S. Copenhagen, April 28, 2017 - Zealand Pharma (`Zealand`) reports Q1 2017 royalty revenue from Sanofi`s sales of Lyxumia®/Adlyxin(TM) (lixisenatide) of DKK 5.1 million and from Soliqua® 100/33 of DKK 2.9 million. Lixisenatide is a once-daily prandial GLP-1 receptor agonist for the treatment of patients with type 2 diabetes and was invented by Zealand....